Latest News and Press Releases
Want to stay updated on the latest news?
-
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
-
积极的FIH安全性和耐受性数据支持将CBX-12推进到多项II期研究结果显示疗效的早期迹象，伴有良好的安全性 康涅狄格州纽黑文, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Cybrexa...
-
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
-
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
-
Cybrexa用于实体肿瘤的主要治疗候选药物CBX-12在既往接受过多种治疗方案的患者人群中显示抗肿瘤活性和强大疗效信号CBX-12和肿瘤免疫疗法联合试验预计将于2022年末启动关于加速批准用于卵巢癌和非小细胞肺癌的计划将根据2022年末开始的2期扩展队列进行评估 康涅狄格州纽黑文, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Cybrexa...
-
CBX-12, Cybrexa’s lead therapeutic candidate for solid tumors, demonstrates anti-tumor activity and robust efficacy signals in a heavily pretreated patient populationCBX-12 and IO therapeutics...
-
NEW HAVEN, Conn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
-
康涅狄格州纽黑文, Sept. 28, 2021 (GLOBE NEWSWIRE) -- 通过自己的alphalex™多肽药物偶联（PDC）平台开发新的治疗方法的专注于肿瘤学的生物技术公司Cybrexa...
-
NEW HAVEN, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
-
NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...